Published in J Virol on July 01, 2000
Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice. J Clin Invest (2007) 1.57
Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector. J Virol (2001) 1.37
Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J Virol (2005) 1.21
Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J Virol (2006) 1.18
Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production. Biotechnol Adv (2009) 1.12
Surface stability and immunogenicity of the human immunodeficiency virus envelope glycoprotein: role of the cytoplasmic domain. J Virol (2004) 1.04
Kunjin virus replicon vectors for human immunodeficiency virus vaccine development. J Virol (2003) 0.91
DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers. J Virol (2015) 0.84
Molecular characterization of the HIV-1 gag nucleocapsid gene associated with vertical transmission. Retrovirology (2006) 0.83
Contribution of virus-like particles to the immunogenicity of human immunodeficiency virus type 1 Gag-derived vaccines in mice. J Virol (2005) 0.83
Post-translational intracellular trafficking determines the type of immune response elicited by DNA vaccines expressing Gag antigen of Human Immunodeficiency Virus Type 1 (HIV-1). Hum Vaccin Immunother (2013) 0.79
Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses. PLoS One (2013) 0.79
Enhanced Immune Response to DNA Vaccine Encoding Bacillus anthracis PA-D4 Protects Mice against Anthrax Spore Challenge. PLoS One (2015) 0.79
Structure and immunogenicity of alternative forms of the simian immunodeficiency virus gag protein expressed using Venezuelan equine encephalitis virus replicon particles. Virology (2007) 0.78
DNA Immunization for HIV Vaccine Development. Vaccines (Basel) (2014) 0.75
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96
Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity (1998) 17.27
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol (1994) 15.93
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science (1997) 15.09
Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1989) 12.54
Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science (1998) 12.05
Heterologous protection against influenza by injection of DNA encoding a viral protein. Science (1993) 10.14
Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc Natl Acad Sci U S A (1990) 8.23
Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med (1997) 5.72
Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature (1994) 5.68
DNA vaccines. Annu Rev Immunol (1997) 5.05
Mutations in the N-terminal region of human immunodeficiency virus type 1 matrix protein block intracellular transport of the Gag precursor. J Virol (1993) 4.20
Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med (1998) 4.13
DNA-based immunization by in vivo transfection of dendritic cells. Nat Med (1996) 3.62
Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein. J Virol (1992) 3.44
Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J Virol (1997) 3.28
Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression. J Virol (1992) 3.14
Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. Nucleic Acids Res (1991) 2.92
Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J Immunol Methods (1995) 2.82
Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med (1999) 2.77
HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet (1993) 2.71
Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc Natl Acad Sci U S A (1998) 2.33
DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J Exp Med (1999) 1.93
Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci U S A (1998) 1.93
Human immunodeficiency virus (HIV) nef-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV-infected patients. J Clin Invest (1994) 1.75
Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences. Infect Immun (1999) 1.63
Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology (1995) 1.59
Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunology (1996) 1.52
Absence of recoverable infectious virus and unique immune responses in an asymptomatic HIV+ long-term survivor. AIDS Res Hum Retroviruses (1994) 1.45
Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations. J Immunol (1997) 1.45
Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses. J Virol (1999) 1.43
Cross-clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection. AIDS (1998) 1.35
Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cells. J Immunol (1998) 1.25
Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients. J Virol (1998) 1.18
Mutations in the matrix protein of human immunodeficiency virus type 1 inhibit surface expression and virion incorporation of viral envelope glycoproteins in CD4+ T lymphocytes. J Virol (1997) 1.16
In vivo priming by DNA injection occurs predominantly by antigen transfer. J Immunol (1999) 1.13
Cytotoxic T lymphocyte activity and CD8 subpopulations in children at risk of HIV infection. Clin Exp Immunol (1994) 0.95
Construction and immunogenicity of DNA vaccine plasmids encoding four Plasmodium vivax candidate vaccine antigens. Vaccine (1999) 0.91
Altering the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response. J Virol (1999) 0.86
Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell (1993) 9.93
rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA. Proc Natl Acad Sci U S A (1989) 8.76
The molecular basis of Turcot's syndrome. N Engl J Med (1995) 6.65
The pX protein of HTLV-I is a transcriptional activator of its long terminal repeats. Science (1985) 6.60
Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature (1994) 6.21
Epitaxial BiFeO3 multiferroic thin film heterostructures. Science (2003) 6.14
Cloning and functional analysis of multiply spliced mRNA species of human immunodeficiency virus type 1. J Virol (1990) 5.64
Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res (1995) 5.26
Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol Cell (2001) 5.19
Expression and characterization of the trans-activator of HTLV-III/LAV virus. Science (1986) 5.15
Crystal structure of a MAT alpha 2 homeodomain-operator complex suggests a general model for homeodomain-DNA interactions. Cell (1991) 5.14
The rev (trs/art) protein of human immunodeficiency virus type 1 affects viral mRNA and protein expression via a cis-acting sequence in the env region. J Virol (1989) 5.07
Specific inhibition of Stat3 signal transduction by PIAS3. Science (1997) 4.74
Overland heroin trafficking routes and HIV-1 spread in south and south-east Asia. AIDS (2000) 4.24
Imaging membrane protein helical wheels. J Magn Reson (2000) 3.80
Mismatch repair deficiency in phenotypically normal human cells. Science (1995) 3.55
Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet (2004) 3.45
Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein. J Virol (1992) 3.44
Env and Vpu proteins of human immunodeficiency virus type 1 are produced from multiple bicistronic mRNAs. J Virol (1990) 3.42
Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet (1997) 3.41
Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J Virol (1997) 3.28
Rapid elimination of low-copy DNA sequences in polyploid wheat: a possible mechanism for differentiation of homoeologous chromosomes. Genetics (1997) 3.28
Mutations of GTBP in genetically unstable cells. Science (1995) 3.23
Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif (2012) 3.18
Sequence and secondary structure of Drosophila melanogaster 5.8S and 2S rRNAs and of the processing site between them. Nucleic Acids Res (1979) 3.15
Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression. J Virol (1992) 3.14
Cis-acting sequences responsible for the transcriptional activation of human T-cell leukemia virus type I constitute a conditional enhancer. Proc Natl Acad Sci U S A (1986) 3.12
Regulation of a metallothionein-growth hormone hybrid gene in bovine papilloma virus. Proc Natl Acad Sci U S A (1983) 3.06
Chondrogenic differentiation of mesenchymal stem cells from bone marrow: differentiation-dependent gene expression of matrix components. Exp Cell Res (2001) 3.06
A quantitative bioassay for HIV-1 based on trans-activation. Science (1988) 2.99
Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry (1995) 2.90
The Rev protein of human immunodeficiency virus type 1 promotes polysomal association and translation of gag/pol and vpu/env mRNAs. Mol Cell Biol (1992) 2.83
The structural basis for spectral variations in green fluorescent protein. Nat Struct Biol (1997) 2.79
Automatic adjustment of pacemaker stimulation output correlated with continuously monitored capture thresholds: a multicenter study. European Microny Study Group. Pacing Clin Electrophysiol (1998) 2.76
Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci (2000) 2.75
A molecular, isozyme and morphological map of the barley (Hordeum vulgare) genome. Theor Appl Genet (1993) 2.66
Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions. J Virol (1999) 2.66
Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature (1998) 2.65
A katanin-like protein regulates normal cell wall biosynthesis and cell elongation. Plant Cell (2001) 2.63
Co-localization of HIV-1 Nef with the AP-2 adaptor protein complex correlates with Nef-induced CD4 down-regulation. EMBO J (1997) 2.57
Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol (1997) 2.52
Complex splicing in the human T-cell leukemia virus (HTLV) family of retroviruses: novel mRNAs and proteins produced by HTLV type I. J Virol (1992) 2.52
MSH2 deficient mice are viable and susceptible to lymphoid tumours. Nat Genet (1995) 2.49
Expression of human immunodeficiency virus type 1 vif and vpr mRNAs is Rev-dependent and regulated by splicing. Virology (1991) 2.43
Genome comparisons reveal a dominant mechanism of chromosome number reduction in grasses and accelerated genome evolution in Triticeae. Proc Natl Acad Sci U S A (2009) 2.32
The promoter-regulatory region of the major immediate-early gene of human cytomegalovirus responds to T-lymphocyte stimulation and contains functional cyclic AMP-response elements. J Virol (1989) 2.32
The human poly(A)-binding protein 1 shuttles between the nucleus and the cytoplasm. J Biol Chem (1998) 2.23
NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene (2011) 2.22
Tat and Rev: positive regulators of HIV gene expression. AIDS (1990) 2.18
Feedback regulation of human immunodeficiency virus type 1 expression by the Rev protein. J Virol (1990) 2.17
Identification of trans-dominant HIV-1 rev protein mutants by direct transfer of bacterially produced proteins into human cells. Nucleic Acids Res (1990) 2.14
Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell (1998) 2.00
Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. J Virol (2000) 2.00
The Aspergillus cytoplasmic dynein heavy chain and NUDF localize to microtubule ends and affect microtubule dynamics. Curr Biol (2001) 1.96
MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene (2011) 1.94
Vav2 is an activator of Cdc42, Rac1, and RhoA. J Biol Chem (2000) 1.93
Injecting drug use and HIV infection in southwest China. AIDS (1994) 1.91
Different sites of interaction for Rev, Tev, and Rex proteins within the Rev-responsive element of human immunodeficiency virus type 1. J Virol (1990) 1.90
Elements distinct from human immunodeficiency virus type 1 splice sites are responsible for the Rev dependence of env mRNA. J Virol (1994) 1.88
A novel human immunodeficiency virus type 1 protein, tev, shares sequences with tat, env, and rev proteins. J Virol (1990) 1.87
The posttranscriptional control element of the simian retrovirus type 1 forms an extensive RNA secondary structure necessary for its function. J Virol (1996) 1.85
Structural basis of the recognition of the dishevelled DEP domain in the Wnt signaling pathway. Nat Struct Biol (2000) 1.85
Identification and characterization of virus assembly intermediate complexes in HIV-1-infected CD4+ T cells. Virology (1998) 1.85
The role of nucleocapsid of HIV-1 in virus assembly. Virology (1998) 1.84
Role for ceramide in cell cycle arrest. J Biol Chem (1995) 1.83
Two subtypes of HIV-1 among injection-drug users in southern China. Lancet (1998) 1.82
Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Dev Genet (1999) 1.80
The inducibly expressed GTPase localizes to the endoplasmic reticulum, independently of GTP binding. J Biol Chem (1997) 1.75
Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline. Proc Natl Acad Sci U S A (1998) 1.72
A bioassay for HIV-1 based on Env-CD4 interaction. AIDS Res Hum Retroviruses (1990) 1.70
Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray. J Cancer Res Clin Oncol (2002) 1.69
Development and applications of enhanced green fluorescent protein mutants. Biotechniques (1998) 1.68
Gamma-S crystallin gene (CRYGS) mutation causes dominant progressive cortical cataract in humans. J Med Genet (2005) 1.68
Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. Am J Transplant (2008) 1.68
Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res (1995) 1.67
Cross-activation of the Rex proteins of HTLV-I and BLV and of the Rev protein of HIV-1 and nonreciprocal interactions with their RNA responsive elements. New Biol (1989) 1.66
Role for ceramide as an endogenous mediator of Fas-induced cytotoxicity. Proc Natl Acad Sci U S A (1995) 1.62
Mechanism of translation of monocistronic and multicistronic human immunodeficiency virus type 1 mRNAs. Mol Cell Biol (1992) 1.61
Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia. J Biol Chem (1994) 1.57
Interaction of the human immunodeficiency virus type 1 nucleocapsid with actin. J Virol (1999) 1.57
Intracellular trafficking and interactions of the HIV-1 Tat protein. Virology (1998) 1.57
Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost (2012) 1.52
Rapidly and slowly replicating human immunodeficiency virus type 1 isolates can be distinguished according to target-cell tropism in T-cell and monocyte cell lines. Proc Natl Acad Sci U S A (1989) 1.51
Strong constraints on the rare decays B(s)(0) → μ+ μ- and B0 → μ+ μ-. Phys Rev Lett (2012) 1.50
Target imbalance: disparity of Borrelia burgdorferi genetic material in synovial fluid from Lyme arthritis patients. J Infect Dis (1994) 1.50
Paraptosis: mediation by MAP kinases and inhibition by AIP-1/Alix. Cell Death Differ (2004) 1.50
First observation of the decays B(0) → D(+)K(-)π(+)π(-) and B(-) → D(0)K(-)π(+)π(-). Phys Rev Lett (2012) 1.50
Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2. J Biol Chem (1997) 1.49
Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene (2001) 1.48
HIV-1 subtype C in China. Lancet (1995) 1.48
The histopathology of fibrous dysplasia of bone in patients with activating mutations of the Gs alpha gene: site-specific patterns and recurrent histological hallmarks. J Pathol (1999) 1.48
Polymerase delta variants in RER colorectal tumours. Nat Genet (1995) 1.47
Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine. Structure (1995) 1.47
Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Res Hum Retroviruses (1996) 1.46